C07K16/109 - CPC Classification Index

#1

20250215048

2025-07-03

ASSEMBLED GLYCOPROTEINS

#2

20240366972

2024-11-07

Chimeric Antigen Receptor-Modified NK-92 Cells

#3

20240238623

2024-07-18

Chimeric Antigen Receptor-Modified NK-92 Cells

#4

20240043509

2024-02-08

Biological Therapeutics for Infection-Relating Disorders or Conditions

#5

20230340085

2023-10-26

LENTIVIRAL VECTOR EXPRESSING MEMBRANE-ANCHORED OR SECRETED ANTIBODY

#6

20230124977

2023-04-20

CROSS-REACTIVE ANTIBODIES AND USES THEREOF

#7

20220401485

2022-12-22

Chimeric antigen receptor-modified NK-92 cells

#8

20220259292

2022-08-18

A METHOD OF TREATING HBV INFECTION BY USING ANTI-PRE-S1 HBV ANTIBODIES

#9

20220185870

2022-06-16

HIV/HCV CROSS-REACTIVE ANTIBODIES AND USES THEREOF

#10

20220119502

2022-04-21

KAWASAKI DISEASE ANTIBODIES IDENTIFY HEPACIVIRUS PEPTIDES

#11

20220112272

2022-04-14

Compositions and methods for identifying and sorting antigen-specific B cells

#12

20220033479

2022-02-03

ANTI-HEPATITIS C VIRUS ANTIBODIES

#13

20210260116

2021-08-26

Chimeric antigen receptor-modified NK-92 cells

#14

20210231665

2021-07-29

Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies

#15

20210095010

2021-04-01

Compositions and methods for modified b cells expressing reassigned biological agents

#16

20200181242

2020-06-11

Compositions and methods for identifying and sorting antigen-specific B cells

#17

20200141937

2020-05-07

DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES

#18

20200033344

2020-01-30

DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES

#19

20190352385

2019-11-21

Compositions and methods for modified B cells expressing reassigned biological agents

#20

20190298830

2019-10-03

Neutralizing human monoclonal antibody 8D6 against HCV infection

#21

20190284230

2019-09-19

Method for preparing multimeric forms of the hepatitis c virus (HCV) envelope glycoprotein 2 (HCV E2)

#22

20190270792

2019-09-05

Biological therapeutics for infection-relating disorders or conditions

#23

20190233503

2019-08-01

METHOD OF MANUFACTURING PROTHROMBIN COMPLEX CONCENTRATE FROM FRACTION III AND NON-PROTHROMBIN COMPLEX CONCENTRATE FROM FRACTION IV

#24

20190170753

2019-06-06

HCV core and minicore binding molecules

#25

20190153388

2019-05-23

Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin

#26

20190144528

2019-05-16

Immunoglobulins directed to bacterial, viral and endogenous polypetides

#27

20180371064

2018-12-27

Lentiviral vector expressing membrane-anchored or secreted antibody

#28

20180292408

2018-10-11

CAMELID SINGLE-DOMAIN HCV ANTIBODIES AND METHODS OF USE

#29

20180215817

2018-08-02

Compositions and methods for modified B cells expressing reassigned biological agents

#30

20180136211

2018-05-17

METHODS AND DEVICES FOR DETECTING HEPATITIS C VIRUS

#31

20170313764

2017-11-02

Hepatitis C virus specific antibody

#32

20170283484

2017-10-05

Anti-hepatitis C antibodies and antigen binding fragments thereof

#33

20170233458

2017-08-17

METHOD OF MANUFACTURING INTRAVENOUS IMMUNOGLOBULIN FROM FRACTION III

#34

20170121390

2017-05-04

Method for neutralizing hepatitis C virus, fully human monoclonal antibody against hepatitis C virus (variants), composition of fully human monoclonal antibodies against hepatitis C virus and hybrid mouse/human producer cell line of fully human monoclonal antibodies against hepatitis C virus (variants)

#35

20170107273

2017-04-20

ANTIBODY HAVING INFECTION-INHIBITING ACTIVITY AGAINST HEPATITIS C VIRUS

#36

20170052184

2017-02-23

Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies

#37

20170052183

2017-02-23

Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies

#38

20170043011

2017-02-16

Synthetic hepatitis C polypeptide and methods of making and using same

#39

20160355783

2016-12-08

Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin

#40

20160291020

2016-10-06

HCV core lipid binding domain monoclonal antibodies

#41

20160280747

2016-09-29

ANTICALINS

#42

20160024186

2016-01-28

Biological therapeutics for infection-relating disorders or conditions

#43

20150368668

2015-12-24

HCV E2 construct compositions and methods

#44

20150330980

2015-11-19

METHODS AND KITS FOR THE DETECTION OF VIRAL INFECTIONS

#45

20150291684

2015-10-15

Hepatitis C virus neutralizing antibodies and methods

#46

20150283177

2015-10-08

Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen

#47

20150239959

2015-08-27

Antibodies Directed Against Hepatitis C Virus E1E2 Complex, Compositions of HCV Particles, and Pharmaceutical Compositions

#48

20150210773

2015-07-30

Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen

#49

20150203572

2015-07-23

Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen

#50

20150177242

2015-06-25

Combination hepatitis C virus antigen and antibody detection method

#51

20150175700

2015-06-25

Polyclonal bispecific antibody compositions and method of use

#52

20150147749

2015-05-28

Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen

#53

20150118242

2015-04-30

Hepatitis C virus neutralizing antibody

#54

20150079605

2015-03-19

Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen

#55

20150010578

2015-01-08

Delivery of proteins using adeno-associated virus (AAV) vectors

#56

20140348866

2014-11-27

Method of inducing a cross-reactive HIV-1 immune response by administering a composition comprising the GBV-C E2 protein

#57

20140322204

2014-10-30

TREATMENT AND PREVENTION OF VIRAL INFECTIONS

#58

20140314761

2014-10-23

Polypeptides having antiviral activity and methods for use thereof

#59

20140302082

2014-10-09

Nucleic acid construct comprising nucleic acid derived from genome of hepatitis C virus of genotype 1B, hepatitis C virus genome-replicating cells transfected with the same, and method for producing infectious hepatitis C virus particles

#60

20140286995

2014-09-25

Nucleic acid construct comprising nucleic acid derived from genome of hepatitis C virus of genotype 3a

#61

20140272931

2014-09-18

HCV core lipid binding domain monoclonal antibodies

#62

20140134175

2014-05-15

HUMAN ANTIBODIES AGAINST HEPATITIS C VIRUS (HCV) AND USES THEREOF

#63

20140120127

2014-05-01

Recombinant HCV E2 glycoprotein

#64

20140046034

2014-02-13

ANTIBODY HAVING ACTIVITY OF INHIBITING HEPATITUS C VIRUS (HCV) INFECTION AND USE THEREOF

#65

20130224246

2013-08-29

Modified Hepatitis C virus proteins

#66

20130164784

2013-06-27

Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen

#67

20130164277

2013-06-27

Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen

#68

20130052187

2013-02-28

Antibodies Directed Against Hepatitis C Virus E1E2 Complex, Compositions of HCV Particles, and Pharmaceutical Compositions

#69

20120288510

2012-11-15

Human antibodies against hepatitis C virus (HCV) and uses thereof

#70

20120269813

2012-10-25

Polyclonal bispecific antibody compositions and method of use

#71

20120232133

2012-09-13

Delivery of proteins using adeno-associated virus (AAV) vectors

#72

20120220758

2012-08-30

Antibody having activity of inhibiting hepatitis C virus (HCV) infection and use thereof

#73

20120088718

2012-04-12

HCV-derived polypeptides and uses thereof

#74

20120039846

2012-02-16

Hepatitis C antibodies and uses thereof

#75

20120027722

2012-02-02

HEPATITIS C VIRUS COMBINATION THERAPY

#76

20120009196

2012-01-12

MONOCLONAL ANTIBODIES AGAINST HEPATITIS C VIRUS CORE PROTEIN

#77

20110311551

2011-12-22

ANTIBODIES DIRECTED AGAINST HEPATITIS C VIRUS E1E2 COMPLEX, COMPOSITIONS OF HCV PARTICLES, AND PHARMACEUTICAL COMPOSITIONS

#78

20110311550

2011-12-22

AGENTS FOR HCV TREATMENT

#79

20110294194

2011-12-01

Efficient cell culture system for hepatitis C virus genotype 2B

#80

20110287410

2011-11-24

Hepatitis-C virus testing

#81

20110263436

2011-10-27

Recombinant antibodies against hepatitis C virus and methods of obtaining and using same

#82

20110256140

2011-10-20

Anti-HCV monoclonal antibody as a medicament for the therapeutic treatment and prevention of HCV infections

#83

20110201014

2011-08-18

Antibody binding to envelope protein 2 of hepatitis C virus and method for identifying genotype of hepatitis C virus using the same

#84

20110097332

2011-04-28

Composition and Method of Use for HCV Immunization

#85

20110045020

2011-02-24

Nucleic acid comprising chimeric gene derived from hepatitis C virus

#86

20110014209

2011-01-20

Recombinant HCV E2 glycoprotein

#87

20110002926

2011-01-06

Hepatitis C virus antibodies

#88

20100310586

2010-12-09

Idiotypic vaccine

#89

20100291545

2010-11-18

ANTIBODY HAVING INHIBITORY ACTIVITY ON INFECTION WITH HEPATITIS C VIRUS (HCV) AND USE THEREOF

#90

20100266624

2010-10-21

Hepatitis-C virus testing

#91

20100247522

2010-09-30

Neutralization of HCV

#92

20100183614

2010-07-22

Immunoglobulins directed to bacterial, viral and endogenous polypeptides

#93

20100150918

2010-06-17

CROSS-SPECIES-SPECIFIC BINDING DOMAIN

#94

20100104555

2010-04-29

HCV neutralizing epitopes

#95

20100047896

2010-02-25

Nucleic acid construct containing full length genome of human hepatitis C virus, recombinant full length virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis C virus particle

#96

20090317830

2009-12-24

HEPATITIS C VIRUS NS2/3 ASSAY

#97

20090311248

2009-12-17

Hepatitis C Virus Neutralizing Antibodies

#98

20090252745

2009-10-08

Amino acids in the HCV core polypeptide domain 3 and correlation with steatosis

#99

20090202482

2009-08-13

Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes

#100

20090186023

2009-07-23

Antibodies directed against hepatitis C virus E1E2 complex, compositions of HCV particles, and pharmaceutical compositions

#101

20090170063

2009-07-02

Hcv rna having novel sequence

#102

20090162373

2009-06-25

Materials and methods for treatment of hepatitis C

#103

20090136515

2009-05-28

Methods of diagnosing, preventing and treating infection with Hepatitis C virus

#104

20090110685

2009-04-30

Treatment and prevention of viral infections

#105

20090104207

2009-04-23

Hepatitis C Virus Neutralizing Antibodies

#106

20090104188

2009-04-23

ANTI-HEPATITIS C VIRUS ANTIBODY AND USES THEREOF

#107

20090010932

2009-01-08

Method for inhibiting HIV-1 replication utilizing anti-GBV-C E2 antibodies

#108

20080274144

2008-11-06

HCV E1 COMPRISING SPECIFIC DISULFIDE BRIDGES

#109

20080248042

2008-10-09

Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc

#110

20080241855

2008-10-02

Method for simultaneously detecting an antigen of, and an antibody against, an infectious microorganism

#111

20080241162

2008-10-02

Human monoclonal antibody Fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity

#112

20080220019

2008-09-11

Nucleic acid construct containing fulllength genome of human hepatitis C virus, recombinant fulllength virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis C virus Particle

#113

20080138894

2008-06-12

PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE

#114

20080131912

2008-06-05

Recombinant antibodies against hepatitis C virus and methods of obtaining and using same

#115

20080113339

2008-05-15

Combination hepatitis C virus antigen and antibody detection method

#116

20080044807

2008-02-21

Method of detecting hepatitis C virus

#117

20070269460

2007-11-22

Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use

#118

20070141701

2007-06-21

HEPATITIS C VIRUS NS2/3 ASSAY

#119

20070128721

2007-06-07

Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use

#120

20070128221

2007-06-07

Hepatitis-C virus testing

#121

20070032635

2007-02-08

Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes

#122

20070026502

2007-02-01

Specificity exchangers that redirect antibodies to a pathogen

#123

20070026425

2007-02-01

Hepatitis C virus non-structural NS3/4A fusion gene

#124

20070026003

2007-02-01

Antibodies directed against hepatitis C virus E1E2 complex, compositions of HCV particles, and pharmaceutical compositions

#125

20070014813

2007-01-18

Conserved motif of hepatitis C virus E2/NS1 region

#126

20070014789

2007-01-18

Humanized antibody conjugates and related methods, assays, reagents, and kits

#127

20060292556

2006-12-28

Method of detecting antibodies to HCV

#128

20060292151

2006-12-28

L-SIGN polymorphisms and methods involving use of same

#129

20060234214

2006-10-19

Methods of detecting hepatitis C virus

#130

20060188511

2006-08-24

Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes

#131

20060183699

2006-08-17

Vaccines containing ribavirin and methods of use thereof

#132

20060177454

2006-08-10

Method of promoting an immune response with a bispecific antibody

#133

20060166320

2006-07-27

In vitro expression of the HCV ARFP/F-core‘coding open reading frame

#134

20060153833

2006-07-13

Anti hepatitis C virus antibody and uses thereof

#135

20060115875

2006-06-01

Detection, characterization and treatment of viral infection and methods thereof

#136

20060104980

2006-05-18

Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes

#137

20060094862

2006-05-04

Specificity exchangers that redirect antibodies to a pathogen

#138

20060062801

2006-03-23

Hepatitis C virus non-structural NS3/4A fusion gene

#139

20060034861

2006-02-16

HCV E1 comprising specific disulfide bridges

#140

20050272029

2005-12-08

Hepatitis c viral-like particle purification

#141

20050239058

2005-10-27

Method for the detection, identification, enumeration and confirmation of virally infected cells and other epitopically defined cells in whole blood

#142

20050202418

2005-09-15

HCV peptide compositions

#143

20050118181

2005-06-02

GB virus C (hepatitis G virus) for the treatment of HIV

#144

20050084845

2005-04-21

Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity

#145

20050069865

2005-03-31

Synthetic hcv envelope proteins and their use for vaccination